[
  {
    "ts": null,
    "headline": "Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value",
    "summary": "Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.",
    "url": "https://finnhub.io/api/news?id=55d1529df95faa211f30c69c3af5c9bc27914aaccba3736ed4c24b15134a2681",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734134056,
      "headline": "Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value",
      "id": 131977467,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Learn how to maximize returns by focusing on high-conviction stocks across diverse sectors and using proven investment strategies.",
      "url": "https://finnhub.io/api/news?id=55d1529df95faa211f30c69c3af5c9bc27914aaccba3736ed4c24b15134a2681"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 15",
    "summary": "Stay updated on dividend activity for top companies, including changes in dividends and upcoming ex-dividend and pay dates.",
    "url": "https://finnhub.io/api/news?id=33fc43392efd9cfd584d56169da5b7754635c9c7d87d7a9f028ac564d6f5e124",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734126012,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 15",
      "id": 131975776,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Stay updated on dividend activity for top companies, including changes in dividends and upcoming ex-dividend and pay dates.",
      "url": "https://finnhub.io/api/news?id=33fc43392efd9cfd584d56169da5b7754635c9c7d87d7a9f028ac564d6f5e124"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=f65e593ac7d3875954c3b4e753c98c5f088944f6e797141a2f189806a5e711ef",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734107580,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 132064412,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=f65e593ac7d3875954c3b4e753c98c5f088944f6e797141a2f189806a5e711ef"
    }
  },
  {
    "ts": null,
    "headline": "Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.",
    "summary": "Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.",
    "url": "https://finnhub.io/api/news?id=4f29d1705e9cc01e48299551e1b0219ecf3f31d8527bf8d8ddbb6a25d79e376d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734102180,
      "headline": "Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.",
      "id": 131967903,
      "image": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's Ozempic will become the first and only GLP-1 drug to be shown to reduce progression of kidney disease in adults with Type 2 diabetes.",
      "url": "https://finnhub.io/api/news?id=4f29d1705e9cc01e48299551e1b0219ecf3f31d8527bf8d8ddbb6a25d79e376d"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Omvoh速 (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh速 (mirikizumab), an interleukin-23p19 (IL-23p19) antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.",
    "url": "https://finnhub.io/api/news?id=75da4bee091ba5c1b7e58921367fee4c4eaa7786982c278c5b9305cba796c834",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734095460,
      "headline": "Lilly's Omvoh速 (mirikizumab) recommended by CHMP for approval in the European Union for adults with moderately to severely active Crohn's disease",
      "id": 131970800,
      "image": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh速 (mirikizumab), an interleukin-23p19 (IL-23p19) antagonist, for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.",
      "url": "https://finnhub.io/api/news?id=75da4bee091ba5c1b7e58921367fee4c4eaa7786982c278c5b9305cba796c834"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: positive EU opinion for Crohn's disease",
    "summary": "Eli Lilly has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Omvoh , for adults with moderately to severely...",
    "url": "https://finnhub.io/api/news?id=986f1381b3debc561d0db2811707c9a9280fb33562a6d5d698b377a4d6b81e55",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734086596,
      "headline": "Eli Lilly: positive EU opinion for Crohn's disease",
      "id": 131967123,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly has announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for Omvoh , for adults with moderately to severely...",
      "url": "https://finnhub.io/api/news?id=986f1381b3debc561d0db2811707c9a9280fb33562a6d5d698b377a4d6b81e55"
    }
  },
  {
    "ts": null,
    "headline": "American Century Growth Fund Q3 2024 Commentary",
    "summary": "The broad U.S. stock market posted solid gains that saw a reversal of first-half  trends. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=4ff36e88373737720c7fd00f3c4e9dd534f9310a1128306049df92336f433aad",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734083100,
      "headline": "American Century Growth Fund Q3 2024 Commentary",
      "id": 131966292,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400960132/image_1400960132.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The broad U.S. stock market posted solid gains that saw a reversal of first-half  trends. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=4ff36e88373737720c7fd00f3c4e9dd534f9310a1128306049df92336f433aad"
    }
  },
  {
    "ts": null,
    "headline": "EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly",
    "summary": "-The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it has benefit in treating a sleep disorder without approving it specifically...",
    "url": "https://finnhub.io/api/news?id=df5e5dc22e3d32e1284709bec38086760c9ac5e027324a1306687a3d98205a0e",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734082103,
      "headline": "EU drugs regulator backs Mounjaro's sleep apnea use without fresh approval for Lilly",
      "id": 131966108,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "-The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it has benefit in treating a sleep disorder without approving it specifically...",
      "url": "https://finnhub.io/api/news?id=df5e5dc22e3d32e1284709bec38086760c9ac5e027324a1306687a3d98205a0e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease",
    "summary": "By Colin Kellaher Eli Lilly said a key European regulatory committee has recommended expanded approval of its Omvoh drug for certain adults with the inflammatory bowel disorder Crohn's disease....",
    "url": "https://finnhub.io/api/news?id=b470bff992b7083d615d195b5302314046cfa631121d72e23749cfa78df30101",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734079695,
      "headline": "Eli Lilly Gets Key European Backing for Omvoh in Crohn's Disease",
      "id": 131965655,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Eli Lilly said a key European regulatory committee has recommended expanded approval of its Omvoh drug for certain adults with the inflammatory bowel disorder Crohn's disease....",
      "url": "https://finnhub.io/api/news?id=b470bff992b7083d615d195b5302314046cfa631121d72e23749cfa78df30101"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market",
    "summary": "Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its...",
    "url": "https://finnhub.io/api/news?id=ddece2ac072282cd39b9dca36fa7b0ec40b570bab83c07f4f830e8efe0d258e0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734051846,
      "headline": "Lilly's Mounjaro more popular than Wegovy in UK's private obesity drug market",
      "id": 131959637,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's Mounjaro over Novo Nordisk's Wegovy, online pharmacies say, in a sign the U.S. drugmaker is gaining ground on its...",
      "url": "https://finnhub.io/api/news?id=ddece2ac072282cd39b9dca36fa7b0ec40b570bab83c07f4f830e8efe0d258e0"
    }
  }
]